Fact based stock research
Malinckrodt (NYSE:MNK)


Malinckrodt stock research in summary

mallinckrodt.com


Malinckrodt shares have a BUY rating. They are good value and are safely financed, but show below average growth. We recommend buying and holding Malinckrodt shares.


Latest Obermatt Ranks


Country United Kingdom
Industry Pharmaceuticals
Index S&P MIDCAP
Size class Medium

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Research History: Malinckrodt

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
88
38
89
91
STOCK GROWTH RANKS
59
18
24
33
STOCK SAFETY RANKS
22
9
21
73
COMBINED STOCK RANKS
49
3
60
100

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Malinckrodt in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Malinckrodt; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
84
60
14
40
PROFIT GROWTH
72
72
72
50
STOCK RETURNS
6
20
10
4
CONSOLIDATED RANK: GROWTH
59
18
24
33

Financial reporting date of Growth Rank: 30-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Malinckrodt.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
4
4
6
4
REFINANCING
62
38
46
100
LIQUIDITY
29
24
23
73
CONSOLIDATED RANK: SAFETY
22
9
21
73

Financial reporting date of Safety Rank: 30-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Malinckrodt and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Malinckrodt from June 8, 2018.